CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced the publication of a paper entitled “Treatment of Mammary Carcinomas in HER-2 Transgenic Mice through Combination of Genetic Vaccine and an Agonist of Toll-like Receptor 9” in Clinical Cancer Research (2009, 15, 1575-84) co-authored by scientists from Idera and Merck & Co., Inc. The paper describes a preclinical study evaluating a TLR9 agonist as a vaccine adjuvant in combination with a HER-2/neu plasmid DNA electroporation/adenovirus vaccine candidate.
